A Phase 2b Randomized Trial of Autologous Dendritic Cell Immunotherapy (CMN-001) Plus Standard Treatment of Advanced Renal Cell Carcinoma
Latest Information Update: 05 Oct 2023
At a glance
- Drugs Rocapuldencel T (Primary) ; Everolimus; Ipilimumab; Lenvatinib; Nivolumab
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors CoImmune
Most Recent Events
- 28 Sep 2023 Status changed from recruiting to discontinued.
- 06 Jul 2023 According to a CoImmune Media Release, the company announced the publication of a review of the companys clinical development program evaluating CMN-001to treat metastatic renal cell carcinoma in a Human Vaccines and Immunotherapeutics, a peer-reviewed journal sponsored by the International Society for Vaccines.
- 28 Jul 2022 Planned End Date changed from 1 Mar 2022 to 1 Mar 2024.